CN102614115B - 一种双氯芬酸钠自乳化软膏 - Google Patents
一种双氯芬酸钠自乳化软膏 Download PDFInfo
- Publication number
- CN102614115B CN102614115B CN 201210126343 CN201210126343A CN102614115B CN 102614115 B CN102614115 B CN 102614115B CN 201210126343 CN201210126343 CN 201210126343 CN 201210126343 A CN201210126343 A CN 201210126343A CN 102614115 B CN102614115 B CN 102614115B
- Authority
- CN
- China
- Prior art keywords
- diclofenac sodium
- self
- emulsifier
- emulsion
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960001193 diclofenac sodium Drugs 0.000 title claims abstract description 143
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 title claims abstract description 142
- 239000002674 ointment Substances 0.000 title claims abstract description 92
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000007957 coemulsifier Substances 0.000 claims abstract description 35
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 31
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 28
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 14
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 14
- 238000007670 refining Methods 0.000 claims abstract description 14
- 239000003937 drug carrier Substances 0.000 claims abstract description 11
- 230000001804 emulsifying effect Effects 0.000 claims description 90
- 239000003921 oil Substances 0.000 claims description 48
- 239000000839 emulsion Substances 0.000 claims description 29
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 24
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 24
- -1 polyoxyethylene Polymers 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 19
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 239000004359 castor oil Substances 0.000 claims description 12
- 235000019438 castor oil Nutrition 0.000 claims description 12
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 238000002844 melting Methods 0.000 claims description 11
- 230000008018 melting Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 abstract description 16
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000011159 matrix material Substances 0.000 abstract description 4
- 206010065390 Inflammatory pain Diseases 0.000 abstract description 3
- 238000010579 first pass effect Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 abstract 2
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 239000007788 liquid Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 206010042674 Swelling Diseases 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 206010023232 Joint swelling Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 206010040880 Skin irritation Diseases 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 231100000475 skin irritation Toxicity 0.000 description 7
- 230000036556 skin irritation Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000035617 depilation Effects 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000003475 lamination Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210126343 CN102614115B (zh) | 2012-04-26 | 2012-04-26 | 一种双氯芬酸钠自乳化软膏 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210126343 CN102614115B (zh) | 2012-04-26 | 2012-04-26 | 一种双氯芬酸钠自乳化软膏 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102614115A CN102614115A (zh) | 2012-08-01 |
CN102614115B true CN102614115B (zh) | 2013-05-15 |
Family
ID=46554570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210126343 Expired - Fee Related CN102614115B (zh) | 2012-04-26 | 2012-04-26 | 一种双氯芬酸钠自乳化软膏 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102614115B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151685A (zh) * | 2019-07-01 | 2019-08-23 | 李云昆 | 一种外用止痛组合物及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151285A (zh) * | 1995-12-05 | 1997-06-11 | 中山医科大学科技开发部 | 双氯芬酸软膏及其制备方法 |
CN1249930A (zh) * | 1998-10-07 | 2000-04-12 | 江苏省药物研究所 | 双氯芬酸钾凝胶、软膏及制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US20100099766A1 (en) * | 2008-10-16 | 2010-04-22 | Novartis Ag | Topical NSAID compositions having sensate component |
-
2012
- 2012-04-26 CN CN 201210126343 patent/CN102614115B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151285A (zh) * | 1995-12-05 | 1997-06-11 | 中山医科大学科技开发部 | 双氯芬酸软膏及其制备方法 |
CN1249930A (zh) * | 1998-10-07 | 2000-04-12 | 江苏省药物研究所 | 双氯芬酸钾凝胶、软膏及制备方法 |
Non-Patent Citations (4)
Title |
---|
A.A. Attama et al.The use of solid self-emulsifying systems in the delivery of diclofenac.《International Journal of Pharmaceutics》.2003,第262卷23-28页. |
HPLC-ELSD法测定双氯芬酸钠自乳化缓释片中双氯芬酸钠的含量;霍务贞 等;《广东药学院学报》;20111031;第27卷(第5期);477-479页 * |
The use of solid self-emulsifying systems in the delivery of diclofenac;A.A. Attama et al;《International Journal of Pharmaceutics》;20031231;第262卷;23-28页 * |
霍务贞 等.HPLC-ELSD法测定双氯芬酸钠自乳化缓释片中双氯芬酸钠的含量.《广东药学院学报》.2011,第27卷(第5期),477-479页. |
Also Published As
Publication number | Publication date |
---|---|
CN102614115A (zh) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107998020B (zh) | 一种具有抗过敏功效的护肤霜 | |
CN101869539B (zh) | 一种用于敏感性皮肤修复的脱敏复合纳米乳及其制备方法 | |
CN103655710A (zh) | 一种马钱子总碱微乳及其制剂及制备方法 | |
CN104474551A (zh) | 褪黑素磷脂复合物、其透皮给药制剂及其制备方法 | |
CN102614115B (zh) | 一种双氯芬酸钠自乳化软膏 | |
CN103071149A (zh) | 一种胶原蛋白角鲨烷组合物及其制剂和其制备方法与应用 | |
CN105878315A (zh) | 一种柴胡退热贴及其制备工艺 | |
CN105963243B (zh) | 一种治疗寻常痤疮的龙脑香樟精油缓释乳膏及其制备方法 | |
CN103211758A (zh) | 一种液晶纳米粒透皮剂及其制备方法 | |
CN102614265A (zh) | 一种消肿定痛自乳化软膏 | |
CN102614114B (zh) | 一种维生素e自乳化软膏 | |
CN105250838B (zh) | 一种治疗胼胝的化妆品 | |
JP7369278B2 (ja) | 経皮浸透促進組成物、及びチモロール製剤におけるその適用 | |
CN102940684A (zh) | 一种含红茴香的中药组合物及其制备方法 | |
CN113521290B (zh) | 一种药物组合物、药贴及其制备方法与应用 | |
CN106138083A (zh) | 一种治疗皮肤皴裂的复方中药纳米乳膏 | |
CN105395535B (zh) | 一种含有布洛芬的乳膏药物组合物 | |
CN109528917A (zh) | 一种治疗类风湿性关节炎的朝医方组合物及其乳膏剂的制备方法 | |
CN1857345B (zh) | 一种治疗偏头痛的药物组合物及其制备方法 | |
CN102526112A (zh) | 一种缓释型珍珠明目滴眼液及其制备方法 | |
CN105878427A (zh) | 一种治疗烧烫伤的牡丹籽油复方喷雾剂及制备方法 | |
CN104274584B (zh) | 一种治疗脱发藏药的制备方法 | |
CN112587510B (zh) | 一种神阙穴给药的外用安神助眠制剂 | |
Singh et al. | ANTIFUNGAL MARKER | |
Maheshwari et al. | ANTIFUNGAL MARKER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wei Yu Inventor after: Lou Yuhan Inventor after: Liu Yamin Inventor after: He Yongchao Inventor after: Yang Yanjiao Inventor after: Li Zhenguo Inventor before: Wei Yu Inventor before: Lou Yuling Inventor before: Liu Yamin Inventor before: He Yongchao Inventor before: Yang Yanjiao Inventor before: Li Zhenguo |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WEI YU LOU YULING LIU YAMIN HE YONGCHAO YANG YANJIAO LI ZHENGUO TO: WEI YULOU YUQIAN LIU YAMIN HE YONGCHAO YANG YANJIAO LI ZHENGUO |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130515 Termination date: 20160426 |